Targeting these key players may hold promise for the development of novel therapies for age-related pathologies with aberrant IGF-1 signalling such as type 2 diabetes, skin atrophy, osteoporosis, impaired wound healing, and neurodegenerative disease. Here, IGF1 is linked to osteoporosis.